The stock of Allergan plc (NYSE:AGN) is a huge mover today! This analysis is based on historical data about the stock's performance given the overall trends of the market and particular indicators within the market. The simple logic that a stock's current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run is behind shareholders' inclination toward low P/E stocks. Also, Chairman Brent L. Saunders purchased 4,600 shares of the company's stock in a transaction on Wednesday, December 6th. Finally, Royal Bank of Canada lowered their target price on Allergan from $250.00 to $221.00 and set an outperform rating for the company in a report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. Don't forget to ensure the company can pay its debts by looking at the current ration, which now is 1.2, and the quick ration, which now sits at 1.1.
At the session level, shares of Allergan plc (NYSE:AGN) moved -0.72% from the open. Let's take a look at Allergan's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. More interesting news about Allergan plc (NYSE:AGN) were released by: Investorplace.com and their article: "3 Big Stock Charts for Thursday: Allergan plc Ordinary Shares (AGN), Cummins ..." published on May 11, 2017 as well as Investorplace.com's news article titled: "Buy Allergan Plc Ordinary Shares After the Earnings!" with publication date: November 01, 2017. During the same quarter in the prior year, the firm earned $3.32 earnings per share. equities analysts forecast that Allergan will post 16.27 EPS for the current fiscal year. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion.
The good news is there's still room for Allergan plc (AGN) to grow. The firm's revenue for the quarter was up 11.4% compared to the same quarter a year ago.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Moreover, American Rech And Management Co has 0% invested in Allergan plc (NYSE:AGN) for 33 shares. The stock of Allergan plc (NYSE:AGN) has "Outperform" rating given on Thursday, November 3 by RBC Capital Markets.
ATR remains at 0.25 while Beta component of the stock stands at 1.04. Allergan PLC.'s dividend payout ratio is presently 9.63%. Investors use this figure to figure out a company's size, as opposed to just using total asset or sales figures. Stock buyback plans are often a sign that the company's management believes its shares are undervalued. Dowling Yahnke Limited Liability reported 2,097 shares. (NYSE:AGN) by 13.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The insider, BODINE CHRIS W, now holds 17,098 shares of AGN. The stock was purchased at an average price of $164.77 per share, for a total transaction of $499,253.10.
Allergan declared that its Board of Directors has initiated a stock buyback program on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. The investor is now holding $4.03 million shares due in part to a decrease of 357089 new shares in their portfolio. Finally, Jacobi Capital Management LLC raised its position in Allergan PLC.by 4.9% in the first quarter. LLC now owns 500 shares of the company's stock worth $122,000 after purchasing an additional 385 shares during the last quarter. Howard Hughes Medical Institute acquired a new stake in shares of Allergan during the second quarter worth about $103,000. Baupost Group LLC MA grew its position in Allergan by 21.9% during the 3rd quarter. LLC grew its holdings in shares of Allergan by 334.8% during the second quarter.
The stock showed weekly performance of 1.85%, which was maintained for the month at -7.30%.
Several other institutional investors have also sold shares of the company.
TRADEMARK VIOLATION NOTICE: "Brown Advisory Inc".